SEHK:460Pharmaceuticals
Assessing Sihuan Pharmaceutical Holdings Group’s Valuation After Bireociclib’s New First Line Breast Cancer Approval
Sihuan Pharmaceutical Holdings Group (SEHK:460) drew investor attention after China approved a new first-line indication for its Bireociclib Tablets in HR+/HER2- advanced breast cancer, expanding coverage across all treatment lines.
See our latest analysis for Sihuan Pharmaceutical Holdings Group.
At a share price of HK$1.49, the stock has seen a 6.43% 7 day share price return and a 16.41% 90 day share price return. The 1 year total shareholder return of 150.06% points to strong momentum,...